Prescription digital therapeutic developer Theranica announced it has received FDA 510(k) clearance to use its Nerivio device for migraine prevention in patients 12 and older.
The wearable is worn around the upper arm and controlled with a smartphone. It delivers electrical pulses to stimulate small peripheral nerves, which aims to trigger a conditioned pain modulation response to alleviate...
Theranica, an Israeli prescription digital therapeutics developer focused on migraine care, announced today that it has scored $45 million in Series C funding.
The round was led by New Rhein Healthcare Investors with participation from aMoon, Lightspeed Venture Partners, LionBird, Takoa Invest and Corundum Open Innovation.
The startup announced a $35 million Series B round of funding in 2019 and...
Theranica, an Israeli prescription digital therapeutics developer for migraine and other pain conditions, has received 510(k) clearance from the U.S. Food and Drug Administration for its Nerivio device.
The device has been cleared for acute treatment of episodic or chronic migraine in people 12 years and older.
Nerivio is a wireless, noninvasive remote electrical-stimulation wearable that is worn...
Israel-headquartered MDClone, maker of a Synthetic Data Engine for healthcare, has raised $26m (€23.5m) in a Series B funding round led by aMoon, a VC fund focused on health tech and life sciences, it was announced this week. Existing backers OrbiMed Israel Partners and Lightspeed Venture Partners also participated in the raise.
WHAT THEY DO
According to MDClone, its engine examines original...
This quarter was another busy one for the FDA as it continued to reevaluate its approach to digital health amidst a changing of the guard from Dr. Scott Gottlieb to its new commissioner, Dr. Norman "Ned" Sharpless.
Among its most notable digital health actions of the past few months was the agency’s decision to put out a call for new companies to try out the current framework of its Digital...
With a background in biomedical science and rich experience in medical device venture capital investment, Tomoko Inoue possesses the technical, operational and business knowledge of what makes medtech startups successful – a role perfectly suited for her current role as the CEO of OMRON Ventures.
She believes that in a hyper aging society like Japan, there is a big need for smart infrastructure...
Pain is usually an indication something wrong with the body and the typical approach to pain is to take appropriate medicine that will help alleviate that pain. However, taking painkillers will have some side effects and it is more complicated, or even life-threatening for those who are allergic to certain painkillers.
Imagine a future where pain can be managed or alleviated using a combination...
Theranica, an Israel-based biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, announced on May 28 that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra, utilising Remote Electrical Neuromodulation for the acute treatment of migraine.
The FDA...
Theranica, an Israel-based biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, announced that Omron Ventures has joined its $35M series B funding round, which was announced earlier this March. The investment sum by Omron Ventures has not been disclosed.
Omron Ventures, the venture capital arm of Japan-based Omron Corporation...
Founded in 2016, Theranica, a biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, yesterday announced the closing of its round B of financing, of $35M, led by aMoon, Israel's largest healthcare VC. All existing investors of the company – Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa – participated in...
